Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer.

Molecular cancer therapeutics - 1 Jan 2009

Afshar Sepideh, Asai Tsuneaki, Morrison Sherie L

Abstract excerpt

Immunogenicity caused by the use of nonhuman enzymes in antibody-directed enzyme prodrug therapy has limited its clinical application. To overcome this problem, we have developed a mutant human purine nucleoside phosphorylase, which, unlike the wild-type enzyme, accepts (deoxy)adenosine-based prodrugs as substrates. Among the different mutants of human purine nucleoside phosphorylase tested, a double mutant with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine
Share to Antibodies
Share to Guanosine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Mimicry

Share to Prodrugs

Share to Protein Engineering

Share to Purine-Nucleoside Phosphorylase

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 19139128
DOI: 10.1158/1535-7163.MCT-08-0652
PMCID: PMC2707522

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer.PMID 19139128Read ↗

Structure of a mutant human purine nucleoside phosphorylase with the prodrug, 2-fluoro-2'-deoxyadenosine and the cytotoxic drug, 2-fluoroadenine.Semantic proximity Read ↗

Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system.Semantic proximity Read ↗

Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.Semantic proximity Read ↗

Antibody–Enzyme Fusion Proteins for Cancer TherapySemantic proximity Read ↗

Recent progress of aptamer‒drug conjugates in cancer therapySemantic proximity Read ↗

Annexin-directed β-glucuronidase for the targeted treatment of solid tumors.Semantic proximity Read ↗

Self-immolative nitrogen mustard prodrugs for suicide gene therapy.Semantic proximity Read ↗

A Heterodimeric Glucuronide Prodrug for Cancer Tritherapy: the Double Role of the Chemical AmplifierSemantic proximity Read ↗

Cancer Targeting Radiopeptidomimetics in Molecular Nuclear MedicineSemantic proximity Read ↗

Selective Killing of Tumors Deficient in Methylthioadenosine Phosphorylase: A Novel StrategySemantic proximity Read ↗

Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations.Semantic proximity Read ↗

Design and evaluation of 5'-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.